Related Experiment Video
Updated: Aug 10, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
The long-term course of cyclosporine-associated chronic nephropathy
B D Myers1, R Sibley, L Newton
1Department of Medicine, Stanford University Medical Center, California.
Insights
Cyclosporine (CsA) therapy in heart transplant patients causes chronic kidney injury, leading to reduced kidney function and progressive renal damage. This injury to renal microvessels is often irreversible.
Area of Science:
- Nephrology
- Transplantation Immunology
- Cardiovascular Medicine
Background:
- Cyclosporine (CsA) is a key immunosuppressant in organ transplantation.
- Chronic kidney injury is a significant concern in long-term transplant recipients.
- The specific renal effects of CsA in cardiac transplant recipients require detailed evaluation.
Purpose of the Study:
- To assess the incidence and nature of chronic renal injury in cardiac transplant recipients treated with CsA.
- To compare renal function and pathology in CsA-treated patients versus azathioprine-treated controls.
- To investigate the reversibility and progression of CsA-induced nephropathy.
Main Methods:
- Evaluation of 37 cardiac transplant recipients on CsA (12-24 months) and 24 controls on azathioprine (>24 months).
- Assessment of glomerular filtration rate (GFR), renal vascular resistance (RVR), proteinuria, and blood pressure.
- Histopathological examination of renal biopsies, including arteriolopathy, tubulointerstitial damage, and glomerular changes.
- Longitudinal follow-up over 48 months with dosage adjustments and repeat biopsies in a subset of patients.
Main Results:
- CsA-treated patients showed significantly depressed GFR (47 vs 94 ml/min/1.73 m2) compared to controls.
- CsA therapy was associated with elevated RVR, proteinuria, hypertension, and impaired renin activity.
- Histopathology revealed obliterative arteriolopathy, tubulointerstitial damage, glomerular changes, and mesangial expansion.
- Longitudinal data indicated persistent hypofiltration, increased RVR, and worsening proteinuria even after CsA reduction or withdrawal.
- Three patients developed end-stage renal disease, and further histopathological deterioration was observed.
Conclusions:
- Continuous CsA therapy for over 12 months induces chronic, rarely reversible, and potentially progressive injury to renal microvessels.
- CsA-associated nephropathy involves vascular, interstitial, and glomerular damage.
- Early identification and management strategies are crucial to mitigate long-term renal consequences in CsA-treated patients.
Abstract:
We evaluated a chronic renal injury in 37 cardiac transplant recipients treated for 12 to 24 months with cyclosporine (CsA). Twenty-four cardiac transplant recipients treated with azathioprine for more than 24 months served as controls. Despite equivalent cardiac performance, GFR in those treated with CsA was depressed, 47 +/- 3 versus 94 +/- 4 ml/min/1.73 m2 (P less than 0.001). CsA therapy was also associated with significant elevation of renal vascular resistance (RVR), proteinuria, arterial hypertension, and impaired intrarenal conversion of inactive prorenin to active renin. Histopathological changes associated with CsA included an obliterative arteriolopathy with deposition of proteinaceous material in necrotic arteriolar walls, and associated tubulointerstitial damage. A minority of glomeruli exhibited either ischemic collapse or sclerosis. Area perimeter analysis revealed enlargement of the remaining glomeruli with significant expansion of the mesangium. Longitudinal examination over a 48 month period (N = 15) during which CsA was reduced in dosage or withdrawn revealed persistent hypofiltration, increasingly elevated RVR and heavier proteinuria. Further histopathological deterioration was observed when renal tissue was sampled a second time in six patients, and three members of the experimental group developed end-stage renal disease. We conclude that continuous CsA therapy for more than 12 months causes a chronic injury to renal microvessels that is rarely reversible and potentially progressive.
Related Concept Videos
Nephrons
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Nephrotic Syndrome I : Introduction
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury III: Clinical Manifestations
Diabetic Nephropathy

